MEDICINE OF THE FUTURE STEM CELLS AND GENE THERAPY IN DIABETES by Prof Morsi Arab University of Alexandria
Apr 16, 2017
MEDICINE OF THE FUTURE STEM CELLS AND GENE THERAPY
IN DIABETES
byProf Morsi Arab
University of Alexandria
The mature B-cells as a source (B-cell
transplantation ) is not satisfactory
because they are :
-Limited in number,
- have very limited proliferation capacity.
- and stimulating their growth by growth factors
diminishes their secretory power.
:Stages of Beta cell development and differentiation
- Fetal Entoderm. cell ( high growth potentiality)
- Panc. Duct epith. Cell
- Committed Endoc. precursor cell
- Growth Stimulated B-cell
- Mature B- cell (V. low division capacity)
Non Embryonic Sources of Stem CellsAdult Bone Marrow Umbilical cord Stem Cells Amniotic Fluid Stem Cells Adult Mesenchymal Stem Cells*….etc
The production of induced PluripotentStem (Cells ( iPSC
By genetic reprogramming of mature adult cells to go back to the pluripotent state (adding genes + transcription factors (TF)
- In type 1 Diabetes pancreatic celldestruction results from inflammation + immune reaction
- Adult Mesenchymal Stem Cells ( MSCs) have potent anti- inflammatory and
immune suppressive power .
“Trafficking of Adult Mesenchyme Stem Cells and using Adhesive Molecules towards the Threatened
Pancreatic β cells
saves them from immune destruction”